¼¼°èÀÇ ¸Á¸· Áúȯ Ä¡·á ½ÃÀå
Retinal Disorder Treatment
»óǰÄÚµå : 1777521
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 07¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 375 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,195,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,585,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¸Á¸· Áúȯ Ä¡·á ¼¼°è ½ÃÀåÀº 2030³â±îÁö 221¾ï ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2024³â¿¡ 146¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â ¸Á¸· Áúȯ Ä¡·á ¼¼°è ½ÃÀåÀº 2024³âºÎÅÍ 2030³â±îÁö CAGR 7.2%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 221¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀΠȲ¹Ýº¯¼ºÁõÀº CAGR 7.8%¸¦ ±â·ÏÇÏ¸ç ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 134¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ´ç´¢¸Á¸·º´Áõ ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ µ¿¾È CAGR 5.7%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 40¾ï ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 11.4%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ ¸Á¸· Áúȯ Ä¡·á ½ÃÀåÀº 2024³â¿¡ 40¾ï ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦ ´ë±¹ÀÎ Áß±¹Àº ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGR 11.4%·Î ¼ºÀåÇÏ¿© 2030³â±îÁö 47¾ï ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖ°í, ºÐ¼® ±â°£ µ¿¾È CAGRÀº °¢°¢ 3.6%¿Í 7.0%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 4.8%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°è ¸Á¸· Áúȯ Ä¡·á ½ÃÀå - ÁÖ¿ä µ¿Çâ ¹× ÃËÁø¿äÀÎ Á¤¸®

¸Á¸· Áúȯ Ä¡·á°¡ ÁÖ¸ñ¹Þ´Â ÀÌÀ¯´Â?

´ç´¢¸Á¸·º´Áõ, Ȳ¹Ýº¯¼º, ¸Á¸·Á¤¸ÆÆó¼âÁõ µî ¸Á¸· ÁúȯÀº Àü ¼¼°èÀûÀ¸·Î ½Ã·ÂÀúÇÏÀÇ ÁÖ¿ä ¿øÀÎÀÌ µÇ°í ÀÖ½À´Ï´Ù. °í·ÉÈ­¿Í ´ç´¢, °íÇ÷¾Ð À¯º´·üÀÌ ³ô¾ÆÁö¸é¼­ È¿°úÀûÀÎ ¸Á¸· Ä¡·á¿¡ ´ëÇÑ ¼ö¿ä°¡ Å©°Ô Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¾à¹° Ä¡·á, ·¹ÀÌÀú Ä¡·á ¹× ¼ö¼úÀû °³ÀÔÀÇ ¹ßÀüÀ¸·Î ¸Á¸· ÁúȯÀÇ °ü¸®°¡ °³¼±µÇ¾î ½Ç¸íÀ» ¿¹¹æÇϰí ȯÀÚÀÇ »îÀÇ ÁúÀ» Çâ»ó½Ã۰í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Ç¥Àû »ý¹°ÇÐÀû Á¦Á¦ ¹× À¯ÀüÀÚ ±â¹Ý Ä¡·á¹ýÀÇ µîÀåÀº Ä¡·á »óȲÀ» º¯È­½Ã۰í ÀÖÀ¸¸ç, Áö±Ý±îÁö Ä¡·á°¡ ºÒ°¡´ÉÇß´ø ¸Á¸· Áúȯ ȯÀڵ鿡°Ô »õ·Î¿î Èñ¸ÁÀ» °¡Á®´ÙÁÖ°í ÀÖ½À´Ï´Ù. ¸Á¸· ÁúȯÀÌ °øÁß º¸°Ç¿¡ ½É°¢ÇÑ ¹®Á¦¸¦ ¾ß±âÇÏ´Â °¡¿îµ¥, Çõ½ÅÀûÀÎ Ä¡·á¹ýÀ» ½ÃÀå¿¡ Ãâ½ÃÇϱâ À§ÇÑ ¿¬±¸ °³¹ßÀÌ °¡¼ÓÈ­µÇ°í ÀÖ½À´Ï´Ù.

¸Á¸· Ä¡·áÀÇ ±â¼ú Çõ½ÅÀÌ È¯ÀÚÀÇ ¿¹Èĸ¦ ¾î¶»°Ô °³¼±Çϰí Àִ°¡?

Ç×VEGF(Ç÷°ü³»ÇǼºÀåÀÎÀÚ) Ä¡·áÀÇ È¹±âÀûÀÎ ¹ßÀüÀº ºñÁ¤»óÀûÀÎ Ç÷°ü ¼ºÀåÀ» ¾ïÁ¦ÇÏ°í ½Ã·Â ÀúÇϸ¦ ¿¹¹æÇÔÀ¸·Î½á ¸Á¸· Áúȯ Ä¡·á¿¡ Çõ¸íÀ» ÀÏÀ¸Ä×½À´Ï´Ù. ¼­¹æÇü ÀÓÇöõÆ®, »ýºÐÇØ¼º ¾È±¸ÁÖ»ç µî Àå½Ã°£ ÀÛ¿ëÇÏ´Â ¾à¹°Àü´Þ ½Ã½ºÅÛÀÇ °³¹ß·Î ÀæÀº Ä¡·áÀÇ Çʿ伺À» ÃÖ¼ÒÈ­Çϰí ȯÀÚÀÇ ¼øÀÀµµ¸¦ ³ôÀÏ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ¶ÇÇÑ, À¯ÀüÀÚ Ä¡·á¿Í Áٱ⼼Æ÷¸¦ ÀÌ¿ëÇÑ Ä¡·áÀÇ ¹ßÀüÀº ¸Á¸· ÅðÇ༺ Áúȯ¿¡ ´ëÇÑ À¯¸ÁÇÑ ´ë¾ÈÀ» Á¦°øÇϰí ÀÖ½À´Ï´Ù. Ä¡·á °èȹ¿¡ AI ±â¹Ý Áø´ÜÀ» »ç¿ëÇÏ¿© ¸ÂÃãÇü Ä¡·á¸¦ °­È­ÇÏ¿© ȯÀÚ°¡ ƯÁ¤ Áõ»ó¿¡ °¡Àå È¿°úÀûÀÎ Ä¡·á¸¦ ¹ÞÀ» ¼ö ÀÖµµ·Ï µ½°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¼ú Çõ½ÅÀ¸·Î ½Ã·Â °á°ú°¡ Å©°Ô °³¼±µÇ¾î ¸Á¸· Áúȯ ȯÀÚµéÀÇ Ä¡·á ¼±ÅñÇÀÌ ³Ð¾îÁö°í ÀÖ½À´Ï´Ù.

¸Á¸· Áúȯ Ä¡·áÀÇ ¼ºÀåÀ» °ßÀÎÇÏ´Â ½ÃÀå µ¿ÇâÀº?

»ý¹°ÇÐÀû Á¦Á¦, À¯ÀüÀÚ Ä¡·á, Àç»ýÀÇ·áÀÇ Ã¤ÅÃÀÌ Áõ°¡Çϸ鼭 ¸Á¸· Áúȯ Ä¡·á¿¡ ´ëÇÑ Á¢±Ù ¹æ½ÄÀÌ º¯È­Çϰí ÀÖ½À´Ï´Ù. »õ·Î¿î Ä¡·á¹ý¿¡ ´ëÇÑ ÀÓ»ó½ÃÇèÀÇ È®´ë¿Í ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎÀº ½ÃÀå ¼ºÀåÀ» ´õ¿í °¡¼ÓÈ­Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¿Ü·¡ Ä¡·á¿Í ÃÖ¼Òħ½À Ä¡·á¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϸ鼭 ·¹ÀÌÀú¸¦ ÀÌ¿ëÇÑ ¹Ì¼¼Ä§½À ¼ö¼ú¹ýÀÇ °³¹ß·Î À̾îÁ³½À´Ï´Ù. ¶ÇÇÑ, ¸Á¸· Áúȯ °ü¸®¿¡¼­ AI¿Í µðÁöÅÐ Çコ ±â¼úÀÇ È°¿ëÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ȯÀÚ ¸ð´ÏÅ͸µ°ú Ä¡·áÀÇ °³º°È­°¡ °­È­µÇ°í ÀÖ½À´Ï´Ù.

¸Á¸· Áúȯ Ä¡·á ½ÃÀåÀÇ ÁÖ¿ä ¼ºÀå ÃËÁø¿äÀÎÀº?

¼¼°è ¸Á¸· Áúȯ Ä¡·á ½ÃÀåÀÇ ¼ºÀåÀº »ý¹°ÇÐÀû Ä¡·áÀÇ ¹ßÀü, À¯ÀüÀÚ Ä¡·á ÀÓ»ó ¿¬±¸ÀÇ È®´ë, Çõ½ÅÀûÀÎ Ä¡·á ¿É¼Ç¿¡ ´ëÇÑ Á¢±Ù¼º Áõ°¡·Î ÀÎÇÑ °ÍÀÔ´Ï´Ù. ¸Á¸· ÁúȯÀÇ ºÎ´ã Áõ°¡, °í±Þ Áø´Ü ¹× Ä¡·á ¼Ö·ç¼ÇÀÇ °¡¿ë¼º Áõ°¡°¡ ½ÃÀå ¼ö¿ä¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¿ø°ÝÀÇ·á¿Í µðÁöÅÐ Çコ Ç÷§ÆûÀÇ ÅëÇÕÀ¸·Î ȯÀÚ Âü¿©¿Í Ä¡·á ¼øÀÀµµ°¡ ´õ¿í Çâ»óµÇ°í ÀÖ½À´Ï´Ù. »õ·Î¿î Ä¡·á¹ýÀÌ ¼Ó¼Ó µîÀåÇϸ鼭 ¸Á¸· Áúȯ Ä¡·á ½ÃÀåÀº Áö¼ÓÀûÀÎ ¼ºÀåÀÌ ¿¹»óµÇ¸ç, Àü ¼¼°è ½Ã·Â Ä¡·á¿¡ Çõ½ÅÀûÀÎ ¼Ö·ç¼ÇÀ» Á¦°øÇϰí ÀÖ½À´Ï´Ù.

ºÎ¹®

À¯Çü(Ȳ¹Ýº¯¼ºÁõ, ´ç´¢¸Á¸·º´Áõ, ±âŸ), ÇüÅÂ(Á©, ¾ÆÀÌ ¼Ö·ç¼Ç, ĸ½¶¡¤Á¤Á¦, Á¡¾ÈÁ¦, ¿¬°í), À¯Åë ä³Î(º´¿ø ¾à±¹, ¿Â¶óÀÎ ¾à±¹, ¼Ò¸Å ¾à±¹)

Á¶»ç ´ë»ó ±â¾÷ »ç·Ê

AI ÅëÇÕ

¿ì¸®´Â °ËÁõµÈ Àü¹®°¡¿¡ ÀÇÇÑ ÄÁÅÙÃ÷¿Í AI ÅøÀ» ÅëÇØ ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ Çõ½ÅÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â ÀϹÝÀûÀÎ LLM ¹× ¾÷°èº° SLM Äõ¸®¸¦ µû¸£´Â ´ë½Å ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ¹æ´ëÇÑ ¾çÀÇ ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»ç ¼ÒÀçÁö, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±âÁØÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¸ÅÃâ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº Ç϶ô, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû, °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Retinal Disorder Treatment Market to Reach US$22.1 Billion by 2030

The global market for Retinal Disorder Treatment estimated at US$14.6 Billion in the year 2024, is expected to reach US$22.1 Billion by 2030, growing at a CAGR of 7.2% over the analysis period 2024-2030. Macular Degeneration, one of the segments analyzed in the report, is expected to record a 7.8% CAGR and reach US$13.4 Billion by the end of the analysis period. Growth in the Diabetic Retinopathy segment is estimated at 5.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$4.0 Billion While China is Forecast to Grow at 11.4% CAGR

The Retinal Disorder Treatment market in the U.S. is estimated at US$4.0 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$4.7 Billion by the year 2030 trailing a CAGR of 11.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.6% and 7.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.8% CAGR.

Global Retinal Disorder Treatment Market - Key Trends & Drivers Summarized

Why Is the Treatment of Retinal Disorders Gaining More Attention?

Retinal disorders, including diabetic retinopathy, macular degeneration, and retinal vein occlusion, are among the leading causes of vision loss worldwide. With the growing aging population and increasing prevalence of diabetes and hypertension, the demand for effective retinal treatments has risen significantly. Advances in pharmacotherapy, laser therapy, and surgical interventions have improved the management of retinal diseases, preventing blindness and enhancing patient quality of life. The rise of targeted biologic therapies and gene-based treatments has also transformed the treatment landscape, offering new hope for patients with previously untreatable retinal conditions. As retinal diseases continue to pose significant public health challenges, research and development efforts are accelerating to bring innovative therapies to the market.

How Are Innovations in Retinal Treatment Improving Patient Outcomes?

Breakthroughs in anti-VEGF (vascular endothelial growth factor) therapy have revolutionized the treatment of retinal diseases by reducing abnormal blood vessel growth and preventing vision loss. The development of long-acting drug delivery systems, including sustained-release implants and biodegradable eye injections, has minimized the need for frequent treatments, improving patient compliance. Additionally, advancements in gene therapy and stem cell-based treatments are offering promising alternatives for retinal degenerative disorders. The use of AI-driven diagnostics in treatment planning is also enhancing personalized care, ensuring that patients receive the most effective therapies for their specific conditions. These innovations are significantly improving visual outcomes and expanding treatment options for retinal disease patients.

What Market Trends Are Driving the Growth of Retinal Disorder Treatment?

The increasing adoption of biologic drugs, gene therapy, and regenerative medicine has transformed the approach to retinal disorder treatment. The expansion of clinical trials and regulatory approvals for novel therapies has further accelerated market growth. Additionally, the rising demand for outpatient and minimally invasive treatment options has led to the development of laser-based and microinvasive surgical techniques. The increasing use of AI and digital health technologies in retinal disease management is also enhancing patient monitoring and treatment personalization.

What Are the Key Growth Drivers of the Retinal Disorder Treatment Market?

The growth in the global retinal disorder treatment market is driven by advancements in biologic therapies, expanding clinical research in gene therapy, and increasing access to innovative treatment options. The rising burden of retinal diseases, along with the growing availability of advanced diagnostic and therapeutic solutions, is fueling market demand. The integration of telemedicine and digital health platforms is further improving patient engagement and treatment adherence. As new treatments continue to emerge, the retinal disorder treatment market is expected to experience sustained growth, offering transformative solutions for vision care worldwide.

SCOPE OF STUDY:

The report analyzes the Retinal Disorder Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Macular Degeneration, Diabetic Retinopathy, Others); Form (Gels, Eye Solutions, Capsules & Tablets, Eye Drops, Ointments); Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 36 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â